KR20110053340A - Hpv에 대한 백신 - Google Patents

Hpv에 대한 백신 Download PDF

Info

Publication number
KR20110053340A
KR20110053340A KR1020117004436A KR20117004436A KR20110053340A KR 20110053340 A KR20110053340 A KR 20110053340A KR 1020117004436 A KR1020117004436 A KR 1020117004436A KR 20117004436 A KR20117004436 A KR 20117004436A KR 20110053340 A KR20110053340 A KR 20110053340A
Authority
KR
South Korea
Prior art keywords
hpv
vaccine
dose
vlp
vlps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117004436A
Other languages
English (en)
Korean (ko)
Inventor
도미니크 데샹
산드라 지안니니
니콜라 레크레니에
쟝 스테펜느
마르티네 안느 세실 베텐도르프
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20110053340A publication Critical patent/KR20110053340A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020117004436A 2008-07-31 2009-07-29 Hpv에 대한 백신 Withdrawn KR20110053340A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8510108P 2008-07-31 2008-07-31
US61/085,101 2008-07-31
US17656109P 2009-05-08 2009-05-08
US61/176,561 2009-05-08

Publications (1)

Publication Number Publication Date
KR20110053340A true KR20110053340A (ko) 2011-05-20

Family

ID=41139260

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117004436A Withdrawn KR20110053340A (ko) 2008-07-31 2009-07-29 Hpv에 대한 백신

Country Status (26)

Country Link
US (1) US20110189229A1 (cg-RX-API-DMAC7.html)
EP (1) EP2318042B1 (cg-RX-API-DMAC7.html)
JP (1) JP6022159B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110053340A (cg-RX-API-DMAC7.html)
CN (1) CN102159239A (cg-RX-API-DMAC7.html)
AU (1) AU2009275909A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916732B1 (cg-RX-API-DMAC7.html)
CA (1) CA2732436C (cg-RX-API-DMAC7.html)
CO (1) CO6341567A2 (cg-RX-API-DMAC7.html)
DK (1) DK2318042T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000031A (cg-RX-API-DMAC7.html)
EA (1) EA201170264A1 (cg-RX-API-DMAC7.html)
ES (1) ES2519490T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20141063T1 (cg-RX-API-DMAC7.html)
IL (1) IL210977A0 (cg-RX-API-DMAC7.html)
MA (1) MA32554B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001218A (cg-RX-API-DMAC7.html)
NZ (1) NZ590919A (cg-RX-API-DMAC7.html)
PE (1) PE20110327A1 (cg-RX-API-DMAC7.html)
PL (1) PL2318042T3 (cg-RX-API-DMAC7.html)
PT (1) PT2318042E (cg-RX-API-DMAC7.html)
RS (1) RS53607B1 (cg-RX-API-DMAC7.html)
SI (1) SI2318042T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201400170B (cg-RX-API-DMAC7.html)
WO (1) WO2010012780A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100889B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014021604A1 (ko) * 2012-07-30 2014-02-06 Kim Hong-Jin 인유두종바이러스 바이러스 유사입자의 고효율 정제방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2768172A1 (en) 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
CN102178944A (zh) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
RU2628693C1 (ru) * 2016-11-10 2017-08-21 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ
US20210302427A1 (en) * 2020-03-31 2021-09-30 Shuhari Group, LLC Secure Immunity Information Transmission System And Network
KR20260109890A (ko) * 2024-01-04 2026-07-13 사이안백 엘엘씨 백신 조성물에 증가된 안정성을 제공하는 개선된 제형

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP1732598A4 (en) * 2003-12-31 2009-08-26 Pharmexa Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
KR20070029254A (ko) * 2004-06-16 2007-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는52로부터 선택된 또 다른 hpv 유형에 대한 백신
AR054259A1 (es) * 2005-04-26 2007-06-13 Glaxosmithkline Biolog Sa Vacuna contra virus de papiloma humano (hpv)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014021604A1 (ko) * 2012-07-30 2014-02-06 Kim Hong-Jin 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
US9994618B2 (en) 2012-07-30 2018-06-12 Hong-Jin Kim High efficiency method for purifying human papillomavirus virus-like particles

Also Published As

Publication number Publication date
SMT201400170B (it) 2015-01-15
DK2318042T3 (da) 2014-11-10
BRPI0916732B1 (pt) 2021-06-29
CO6341567A2 (es) 2011-11-21
CA2732436C (en) 2018-01-16
DOP2011000031A (es) 2011-02-28
NZ590919A (en) 2012-10-26
WO2010012780A1 (en) 2010-02-04
EP2318042B1 (en) 2014-08-20
MA32554B1 (fr) 2011-08-01
US20110189229A1 (en) 2011-08-04
CN102159239A (zh) 2011-08-17
PL2318042T3 (pl) 2015-02-27
MX2011001218A (es) 2011-03-15
AU2009275909A1 (en) 2010-02-04
JP6022159B2 (ja) 2016-11-09
BRPI0916732A2 (pt) 2017-01-31
RS53607B1 (sr) 2015-04-30
SI2318042T1 (sl) 2014-12-31
CA2732436A1 (en) 2010-02-04
EP2318042A1 (en) 2011-05-11
PT2318042E (pt) 2014-11-05
JP2011529475A (ja) 2011-12-08
PE20110327A1 (es) 2011-06-29
IL210977A0 (en) 2011-04-28
HRP20141063T1 (hr) 2015-01-02
ES2519490T3 (es) 2014-11-07
ZA201100889B (en) 2012-04-25
EA201170264A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
CN100528226C (zh) 人乳头瘤病毒的病毒样颗粒
JP4546092B2 (ja) ワクチン
EP2318042B1 (en) Vaccine against hpv
MX2011013744A (es) Construcciones novedosas de proteinas del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv.
CA2566620C (en) Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52
KR101359943B1 (ko) Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는 52로부터 선택된 또 다른 hpv 유형에 대한 백신
US7758866B2 (en) Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CN101217975A (zh) 疫苗
HK1128872A (en) Viral antigens

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid